Pivot from developing drugs to commercialising the platform
Value proposition: Enhance existing drugs to address a massive 250B USD (CAGR 10.6%) market
1. Bring drugs to the right place (i.e. to intracellular targets)
2. Enhance properties of drugs (i.e. improve therapeutic window)
3. Reduce discovery cycle time (by dramatically improving profile)
Our advantage is in using our assets as a platform to solve pharma problems
To view Presentation please download PDF attached:
Download this document
